Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Ginseng for Patients on Regorafenib
NCT02581059 · Wake Forest University Health Sciences · PHASE2 · terminated · last registry update 2024-06-26 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funder terminated.” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-28Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Trifluridine/Tipiracil + Regorafenib + Trifluridine/tipiracil + bevacizumab (NCT06992648)
- 2025-03-30Also stopped (terminated): UNICANCER, Regorafenib then Trifluridine/Tipiracil + Trifluridine/Tipiracil then Regorafenib (NCT04450836)
- 2025-01-15Results posted on the registry: Institut du Cancer de Montpellier - Val d'Aurelle, Folfirinox + regorafenib (NCT03828799)
- 2024-12-11Results posted on the registry: ImmunityBio, Inc., Aldoxorubicin Hydrochloride + ALT-803 (NCT03563157)
- 2024-12-11Also stopped (terminated): ImmunityBio, Inc., Aldoxorubicin Hydrochloride + ALT-803 (NCT03563157)
- 2024-11-21Also stopped (withdrawn): City of Hope Medical Center, Balstilimab + Botensilimab (NCT06575725)
- 2024-04-09Results posted on the registry: Merck Sharp & Dohme LLC, pembrolizumab + lenvatinib (NCT04776148)
- 2024-01-10Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 + TAS-102, Regorafenib , Fruquintinib (NCT06199973)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision